In the hierarchy of hyperbaric oxygen therapy’s FDA-cleared indications, some conditions dominate the medical consciousness. Decompression sickness in divers, carbon monoxide poisoning, and non-healing diabetic wounds receive the lion’s share of attention in both medical education and public awareness. Yet tucked within the official list of approved indications is a less celebrated but equally vital application: severe anemia when transfusion is not possible. This indication, recently reviewed in depth in the Undersea and Hyperbaric Medicine journal, represents one of hyperbaric medicine’s most elegant physiological applications—and one that regularly makes the difference between life and death when blood banking reaches its limits.
The clinical scenarios where HBOT becomes essential for anemia management are as varied as they are challenging. Some patients present with religious objections to receiving blood products, most notably Jehovah’s Witnesses, whose faith prohibits transfusion even in life-threatening circumstances. Others face immunological barriers—their bodies have developed antibodies against common red blood cell antigens through prior transfusions or pregnancy, making crossmatch-compatible blood virtually unobtainable. In resource-limited settings or during mass casualty events, the blood supply itself may simply be unavailable. For these patients, hyperbaric oxygen offers a physiological bridge, a temporary life-sustaining measure while the body rebuilds its own red cell mass or while clinicians work to resolve the underlying crisis.
The Physiology of Oxygen Transport Under Pressure
To understand why HBOT works for severe anemia, one must first appreciate the normal physiology of oxygen delivery. Under typical atmospheric conditions, oxygen travels through the bloodstream in two forms: the vast majority bound to hemoglobin molecules within red blood cells, and a tiny fraction—less than 2%—dissolved directly in plasma. Hemoglobin is remarkably efficient at its job, each molecule carrying up to four oxygen atoms and giving arterial blood its characteristic bright red color. This system works beautifully until hemoglobin levels drop catastrophically.
When severe hemorrhage or hemolysis drives hemoglobin concentrations below approximately 3.6 grams per deciliter, the oxygen-carrying capacity becomes inadequate to sustain tissue viability. The mathematics of oxygen debt are unforgiving: accumulated oxygen deficit exceeding 33 liters per square meter of body surface area within four hours of severe hemorrhage is considered unsurvivable without intervention. This is the physiological cliff that severe anemia presents.
Hyperbaric oxygen therapy alters this equation through the direct application of Henry’s Law—the principle that the amount of gas dissolved in a liquid is directly proportional to the pressure of that gas above the liquid. By administering 100% oxygen at pressures of 2 to 3 atmospheres absolute, HBOT dramatically increases the partial pressure of oxygen in the alveoli, which in turn drives substantially more oxygen into physical solution within the plasma.
At 3 ATA breathing pure oxygen, enough oxygen dissolves in plasma to meet resting metabolic demands even in the complete absence of hemoglobin. The dissolved oxygen content increases from roughly 0.3 milliliters per deciliter at sea level breathing room air to approximately 6 milliliters per deciliter under hyperbaric conditions. While this is less than what hemoglobin normally carries, it is sufficient to sustain life and prevent the accumulation of lethal oxygen debt.
The Evidence Base: From Animal Models to Human Cases
The scientific foundation for HBOT in severe anemia rests on a surprisingly robust body of research spanning more than eight decades. Controlled animal studies conducted between 1943 and the 1990s consistently demonstrated survival benefits in HBO₂-treated groups compared to normobaric air controls across multiple hemorrhagic shock models. These investigations established the basic feasibility and physiological rationale that would later guide human application.
The human evidence consists primarily of case reports and case series documenting successful outcomes in profoundly anemic patients who could not receive transfusion. One particularly compelling case from 2026, published in the same Undersea Hyperbaric Medicine issue as the review article, described a patient with G6PD deficiency who developed severe hemolytic anemia and methemoglobinemia following nitrofurantoin administration. Hyperbaric oxygen therapy served as a critical intervention while the patient was stabilized and alternative treatments were instituted.
The evidence hierarchy reaches its peak with a controlled prospective trial in post-hepatectomy patients—arguably the most rigorous clinical investigation of this indication to date. This study provided comparative data supporting the efficacy of HBOT in a defined surgical population experiencing significant blood loss. While not a randomized trial in the modern sense, it represents stronger evidence than the anecdotal reports that comprise much of the hyperbaric literature.
Clinical Integration: The Bridge Strategy
The practical application of HBOT for severe anemia involves more than simply placing the patient in a chamber. Optimal management requires a coordinated strategy combining hyperbaric treatment with concurrent efforts to stimulate endogenous red blood cell production.
During the surface intervals between HBOT sessions—when patients are at normal atmospheric pressure—hematinics and erythropoietin-stimulating agents support bone marrow recovery. Iron supplementation, vitamin B12 and folate as indicated, and recombinant erythropoietin all play roles in accelerating the regeneration of the patient’s own red cell mass. The goal is to shorten the period of dependence on hyperbaric support by maximizing the body’s natural regenerative capacity.
Treatment protocols typically involve sessions at 2 to 3 ATA, with frequency determined by the severity of the anemia and the clinical stability of the patient. Multiple treatments over consecutive days are usually required, as the physiological benefit of each session is temporary—once normobaric conditions return, the additional dissolved oxygen dissipates and tissue oxygenation again becomes dependent on hemoglobin carriage.
The clinical settings where this approach proves valuable are diverse. Operating rooms may initiate HBOT when unexpected surgical bleeding occurs in patients with pre-existing anemia or transfusion limitations. Emergency departments may employ it for trauma victims whose injuries exceed the available blood supply. Intensive care units may use hyperbaric support for patients with hemolytic crises, marrow failure, or complex antibody profiles that make transfusion dangerous or impossible.
Regulatory Standing and Economic Considerations
From a regulatory perspective, severe anemia occupies a unique position among HBOT indications. The American Heart Association classifies it as a Class IIb indication—meaning that while evidence of usefulness and efficacy exists, it is less well-established than Class I indications. This classification reflects both the ethical impossibility of conducting randomized trials in life-threatening anemia and the consistent observational evidence supporting benefit.
Importantly, CMS has long approved coverage for HBOT in severe anemia when transfusion is not possible. This Medicare coverage determination recognizes the life-saving nature of the intervention and the specific clinical circumstances that make transfusion unfeasible. For patients and providers, this means that the financial burden of treatment—which is comparable to the cost of a single unit of packed red blood cells—is typically reimbursable under standard insurance mechanisms.
This favorable economic profile distinguishes severe anemia from many investigational applications of HBOT. While patients seeking hyperbaric treatment for conditions like autism, Alzheimer’s disease, or longevity enhancement typically face substantial out-of-pocket costs, severe anemia treatment is generally covered as an established medical indication. The therapy’s low-technology requirements and excellent safety profile further enhance its cost-effectiveness, particularly when compared to the alternative of prolonged intensive care support in profoundly anemic patients.
The FDA Perspective: A Cleared Indication Within Boundaries
The FDA includes severe anemia among its cleared indications for hyperbaric oxygen therapy, specifically when blood transfusion is not possible. This regulatory approval places the indication in a fundamentally different category from the wellness and longevity applications that have proliferated in recent years. For severe anemia, the agency has recognized that the scientific evidence, while not meeting the gold standard of large randomized trials for ethical reasons, is sufficient to establish safety and efficacy.
However, the FDA’s August 2025 safety letter to healthcare providers serves as an important reminder that even cleared indications require careful attention to device safety protocols. Fire risks, barotrauma, oxygen toxicity, and other potential complications remain relevant considerations in severe anemia treatment. The agency emphasized the critical importance of following manufacturer instructions for safe use of hyperbaric chambers—a reminder that applies with equal force whether the indication is life-threatening decompression sickness or life-threatening anemia.
The FDA’s consumer guidance distinguishes between cleared indications like severe anemia and the numerous unapproved uses for which HBOT is sometimes promoted. Patients seeking hyperbaric treatment should understand that while severe anemia represents a legitimate, evidence-supported application, other marketed benefits may lack similar regulatory validation and scientific foundation.
Limitations and Future Directions
Despite its established role, HBOT for severe anemia has important limitations. The therapy is temporizing rather than curative—it sustains tissue oxygenation while the underlying problem is addressed, but does not itself restore red blood cell mass. Patients require concurrent treatment of hemorrhage, hemolysis, or marrow failure to achieve lasting recovery. The logistical requirements of hyperbaric chambers also limit availability; not every hospital has the infrastructure to provide emergent HBOT, though regional hyperbaric centers can often accommodate transfers when the clinical situation permits.
The evidence base, while supportive, would benefit from additional prospective data collection. Registry studies tracking outcomes across multiple centers could help refine patient selection criteria, optimize treatment protocols, and better define the expected duration of hyperbaric support needed for various clinical scenarios. Such research could strengthen the already favorable risk-benefit profile of this indication.
For clinicians encountering profound anemia in patients who cannot receive transfusion, hyperbaric oxygen therapy represents a valuable—and sometimes essential—therapeutic option. The physiological rationale is sound, the regulatory standing is established, and the clinical evidence, while composed primarily of observational studies, consistently supports benefit. In the calculus of life-threatening oxygen deprivation, HBOT offers a bridge across the gap between crisis and recovery.